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This study investigated the mechanisms underlying tubular apopto-
sis in diabetes by identifying proapoptotic genes that are differen-
tially upregulated by reactive oxygen species in renal proximal
tubular cells (RPTCs) in models of diabetes. Total RNAs isolated
from renal proximal tubules (RPTs) of 20-week-old heterozygous
db/m+, db/db,a n ddb/db catalase (CAT)-transgenic (Tg) mice were
used for DNA chip microarray analysis. Real-time quantitative PCR
assays, immunohistochemistry, and mice rendered diabetic with
streptozotocin were used to validate the proapoptotic gene expres-
sion in RPTs. Cultured rat RPTCs were used to conﬁrm the apoptotic
activity and regulation of proapoptotic gene expression. Addition-
ally, studies in kidney tissues from patients with and without diabe-
t e sw e r eu s e dt oc o n ﬁrm enhanced proapoptotic gene expression in
RPTs. Bcl-2–modifying factor (Bmf) was differentially upregulated
(P , 0.01) in RPTs of db/db mice compared with db/m+a n ddb/db
CAT-Tg mice and in RPTs of streptozotocin-induced diabetic mice in
which insulin reversed this ﬁnding. In vitro, Bmf cDNA overex-
pression in rat RPTCs coimmunoprecipated with Bcl-2, enhanced
caspase-3 activity, and promoted apoptosis. High glucose (25 mmol/L)
induced Bmf mRNA expression in RPTCs, whereas rotenone, cata-
lase, diphenylene iodinium, and apocynin decreased it. Knockdown
of Bmf with small interfering RNA reduced high glucose–induced
apoptosis in RPTCs. More important, enhanced Bmf expression was
detected in RPTs of kidneys from patients with diabetes. These data
demonstrate differential upregulation of Bmf in diabetic RPTs and
suggest a potential role for Bmf in regulating RPTC apoptosis and
tubular atrophy in diabetes. Diabetes 61:474–484, 2012
A
lthough the classic view of diabetic nephropa-
thy (DN) has focused on events leading to glo-
merular dysfunction, the gradual decline of renal
function in later stages of DN is invariably asso-
ciated with tubulointerstitial ﬁbrosis and tubular atrophy (1).
Indeed, tubulointerstitial ﬁbrosis and tubular atrophy appear
to be better predictors of late-stage renal disease progression
than glomerular pathology (2–5). For example, examination
of nephrons from proteinuric diabetic patients shows that
71% of glomeruli display glomerulotubular junction abnor-
malities and 8–17% of glomeruli are atubular glomeruli (6,7).
The mechanisms underlying tubular atrophy are incom-
pletely delineated. Studies have shown that high glucose
(HG) concentrations are associated with increased reactive
oxygen species (ROS) production, which inhibits proximal
tubular function and induces apoptosis (8–10). Apoptosis
has been detected in renal proximal tubular cells (RPTCs)
of diabetic mice (11,12) and rats (13,14) as well as in RPTCs
of diabetic patients (15–17), suggesting that tubular apo-
ptosis may precede tubular atrophy in atubular glomeruli.
Although the link between ROS and tubular apoptosis
seems clear, little is known about the genes involved in HG-
induced RPTC apoptosis or ROS generation.
We previously reported that HG enhances angioten-
sinogen (Agt)g e n ee x p r e s s i o nv i aR O Sg e n e r a t i o ni nr a t
RPTCs in vitro (18,19) and that in vivo overexpression of rat
Agt in RPTCs induces hypertension, albuminuria, and RPTC
apoptosis in diabetes (20). Conversely, we also reported
that RPTC-selective overexpression of catalase (CAT) at-
tenuates ROS generation, tubulointerstitial ﬁbrosis, and tu-
bular apoptosis as well as proapoptotic gene expression in
diabetic mouse kidneys in vivo (21,22). These data suggest
that ROS generation may be directly or indirectly respon-
sible for RPTC apoptosis in diabetes.
We now report that Bcl-2–modifying factor (Bmf), a pro-
apoptotic gene that we identiﬁed via DNA chip microarray
analysis, is differentially upregulated in RPTCs of db/db
mice; we also validated this observation by immunohisto-
chemistry and real-time quantitative PCR (qPCR). We fur-
ther show enhanced Bmf expression in the RPTCs of mice
with streptozotocin (STZ)-induced diabetes as well as in the
kidneys of patients with diabetes. Finally, we found that
Bmf overexpression enhances RPTC apoptosis and that HG
in vitro induces Bmf mRNA expression via ROS generation
and transforming growth factor-b1( T G F - b1) expression.
RESEARCH DESIGN AND METHODS
Chemicals and constructs. D-glucose, D-mannitol, diphenylene iodinium
(DPI, an inhibitor of NADPH oxidase), rotenone (an inhibitor of mitochondrial
electron transport chain complex I), apocynin (an inhibitor of NADPH oxi-
dase), CAT, and monoclonal antibodies against b-actin were purchased from
Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). Normal glucose (5 mmol/L),
Dulbecco’s Modiﬁed Eagle’sM e d i u m( D M E M ) ,1 0 0 3 penicillin/streptomycin,
FBS, and the expression vector pcDNA 3.1 were purchased from InVitrogen,
Inc. (Burlington, ON, Canada). The caspase-3 activity assay kit was purchased
from BD Biosciences Pharmingen (Mississauga, ON, Canada). Anti-Bmf and anti–
c-Myc polyclonal antibodies were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Active human TGF-b1 was purchased from R&D Systems
(Hornby, ON, Canada). Scrambled Silencer Negative Control # 1 small interfering
RNA (siRNA) and siRNAs for TGF-b1 and Bmf were procured from Qiagen, Inc.
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ORIGINAL ARTICLE(Toronto, ON, Canada) and Ambion, Inc. (Austin, TX), respectively. Oligonu-
cleotides were synthesized by InVitrogen, Inc. Restriction enzymes were pur-
chased from InVitrogen, Inc. or Roche Biochemicals (Laval, QC, Canada).
CAT cDNA was a gift from Dr. Paul E. Epstein (University of Louisville,
Louisville, KY). The plasmid pKAP2 containing the kidney-speciﬁc androgen-
regulated protein (KAP) promoter responsive to testosterone stimulation was
obtained from Dr. Curt Sigmund (University of Iowa, Iowa, IA) and has been
described elsewhere (23).
Full-length rat Bmf cDNA was cloned from immortalized Wistar rat RPTCs
(24) by conventional RT-PCR. Sense and antisense primers corresponding to
nucleotides N+242 to N+265 (59-ATG GAG CCA CCT CAG TGT GTG-39)a n d
N+799 to N+779 (59-TCA CCA GGG ACC CAC CCC TTC-39)o fr a tB m fc D N A
(NM_139258.1) were used in real-time PCR. Rat Bmf cDNA was subcloned into
the pCMV-Myc mammalian expression vector containing the human cytomeg-
alovirus promoter (CMV) (Clontech, Mountainview, CA), which fused an NH2-
terminal c-Myc epitope.
Generation of db/db transgenic mice overexpressing rat CAT. Trans-
genic (Tg) mice (C57Bl/6 background) overexpressing rat CAT (rCAT) in
RPTCs (line #688) and homozygous db/db CAT-Tg mice were created in our
laboratory (J.S.D.C.) and have been described previously (21,22). The db/db
and db/db CAT-Tg mice were used at age 20 weeks. Non-Tg, age- and sex-
matched db/m+ littermates served as controls. The physiologic parameters of
db/m+, db/db,a n ddb/db CAT-Tg mice are displayed in Supplementary Table
III. All animals received standard mouse chow and water ad libitum. Animal
care and all procedures were approved by the CHUM animal committee.
Mouse RPT isolation and DNA microarray analysis. Animals were killed at
age 20 weeks. The left and right kidneys were harvested immediately for im-
munohistochemistry and RPT isolation by Percoll gradient (25), respectively,
as previously described (26).
Aliquots of freshly isolated mouse RPTs were immediately processed for
total RNA isolation and gene chip microarray analysis. Brieﬂy, total RNAs from
three mice from each group were puriﬁed and reverse-transcribed into cDNA,
which, in turn, served as the template for the generation of biotin-labeled cRNA
(Enzo kit, Affymetrix, Inc., Santa Clara, CA), and then hybridized to Affymetrix
Mouse Genome 430 2.0 microarray chips (Affymetrix, Inc.), according to the
manufacturer’s protocol. Affymetrix Mouse 430 A 2.0 chips contain ;45,000
probe sets, corresponding to more than 39,000 mouse transcripts. The data
were analyzed by computer with R statistical language (version 2.51). Affylm-
GUI (version 1.10.5) software and the LIMMA package (version 2.10.5) of the
Bioconductor Library (release 2.0) were used for data analysis (27–30). The
GCRMA (Gene Chip Robust Multi-array Average) algorithm was used for back-
ground correction of the data (31), and a linear model ﬁt was undertaken on
different contrasts representing the desired group comparisons (i.e., db/db vs.
heterozygous db/m+m i c e ,db/db mice vs. db/db CAT-Tg mice). A list of nor-
malized data (genes linked to the apoptotic pathway) from all probe sets rep-
resentedon the chips was produced, and classiﬁcation was performed by ﬁltering
based on P , 0.05. The Gene Ontology database (32) for the different probe sets
served to further select genes involved in the apoptosis process with P , 0.01.
Real-time qPCR assays for gene expression. Total RNA was used in real-time
qPCR to quantify the amount of Bmf mRNA expressed in mRPTs according to
previously described methods (20). Forward (59-CCCTTGGGGAGCAGCCCCCTG-39)
and reverse (59-GCCGATGGAACTGGTCTGCAA-39) primers of Bmf (NM_139258)
and forward (59-ATGCCATCCTGCGTCTGGACCTGGC-39) and reverse
(59-AGCATTTGCGGTGCACGATGG-39) primers of b-actin (NM_031144) were used.
Immunohistochemistry. Immunohistochemical staining for Bmf was per-
formed by standard avidin-biotin-peroxidase complex method (ABC Staining
System, Santa Cruz Biotechnology, Inc.) as previously described (20–22).
Induction of diabetes. Adult male mice (C57Bl/6 background) were rendered
diabetic with STZ, as previously described (20,21). Blood glucose was moni-
tored twice weekly; mice were killed at 4 weeks after STZ administration. Both
kidneys were removed, decapsulated, and weighed together. The physiologic
parameters of nondiabetic and diabetic mice are displayed in Supplementary
Table IV. Left and right kidneys were processed for immunohistochemistry
and RPT isolation, respectively (20–22).
Cell culture. Immortalized rat RPTCs at passages 13–18 were used in the
current study using culture conditions reported previously (18,19). Brieﬂy, the
cells were synchronized for 24 h in serum-free 5 mmol/L glucose DMEM at 80–
90% conﬂuence, preincubated in 5 mmol/L glucose DMEM containing 1% de-
pleted FBS for 30 min, and then 20 mmol/L D-mannitol (for normalization of
osmolality) or 20 mmol/L D(+)-glucose were added in the absence or presence
of rotenone (1 3 10
26 mol/L), DPI (5 3 10
26 mol/L), apocynin (10
25 mol/L), or
CAT (300 units/mL). The cells were then cultured for an additional 24 h, after
which they were harvested and RNA was isolated for subsequent analysis for
Bmf and b-actin mRNA quantiﬁcation by real-time qPCR. To analyze ROS and
hydrogen peroxide (H2O2) generation, cells were harvested and subjected to
the lucigenin assay (18,19) and H2O2 measurement kit (Hydrogen Peroxide
Assay Kit, National Diagnostics, Atlanta, GA).
Transfections, apoptosis, and caspase-3 activity assays. The pCMV-Myc
mammalian expression vector containing N-terminally Myc-tagged rat Bmf
(Supplementary Fig. 1) was transiently transfected into RPTCs using Lip-
ofectamine 2000 (InVitrogen). Cells were then incubated for 24 h in 5 mmol/L
D-glucose plus 20 mmol/L D-mannitol (normal glucose) or 25 mmol/L D-glucose
(HG) medium and then analyzed for apoptosis by transferase-mediated
dUTP nick-end labeling (TUNEL) assay, followed by DAPI staining (TUNEL
kit, Roche Diagnostics). The percentage of apoptotic RPTCs was estimated
semiquantitatively. For each group, 8–9 ﬁelds (original magniﬁcation 3200)
were randomly selected, and the captured TUNEL and DAPI images were
overlayed using National Institutes of Health ImageJ (http://rsb.info.nih.gov/ij/)
software. Cells labeled with both TUNEL and DAPI were noted as TUNEL-
positive. The total number of TUNEL-positive cells was divided by the number
of DAPI-stained cells and multiplied by 100 to derive the percentage of apo-
ptotic cells per ﬁeld. In some experiments, cells were harvested for caspase-3
activity assay and anti-Myc immunoblotting to conﬁrm fusion gene expression.
Caspase-3 activity was quantiﬁed ﬂuorimetrically (20–22). Raw data were then
normalized by cell lysate protein concentrations.
Coimmunoprecipitation of Myc-Bmf with Bcl-2 and Western blotting.
Coimmunoprecipitation (co-IP) of Myc-Bmf with Bcl-2 was performed accord-
ing to previously described methods (33).
Bmf immunostaining of kidney biopsy samples of diabetic and non-
diabetic patients. Six kidney biopsy samples (parafﬁn sections) for immu-
nostaining were obtained from the Department of Pathology of the CHUM.
These studies were approved by the CHUM ethics committee, and all patients
provided informed consent.
DNA gene chip analysis of human diabetic and nondiabetic kidneys.
Human renal biopsy samples were obtained from a multicenter study, the
European Renal cDNA Bank-Kröner-Fresenius-Biopsy Bank (ERCB-KFB); all
patients provided informed consent according to guidelines of each respective
local ethics committee. DNA gene chip analysis was performed as previously
described (34–36). Twenty-ﬁve individual biopsy samples, stratiﬁed by a refer-
ence pathologist at the ERCB, were analyzed, using 18 preimplantation kidney
biopsy samples from healthy living donors as control samples and 7 samples for
each region of the kidney (tubules, glomeruli, etc.) from 9 DN patients with type
2 diabetes mellitus (T2DM). Samples were processed as described, and mi-
croarrays from microdissected renal compartments were hybridized to an Affy
133plus chip (34–36). Image ﬁles were processed and normalized using the
ExpressionFileCreator module in GenePattern pipeline (http://genepattern.
broadinstitute.org). A custom CDF (Chip Description Files) annotation ﬁle
from Brainarray (http://brainarray.mbni.med.umich.edu) was used to map the
probes to the respective genes based on the updated genome annotation. The
normalized log-transformed data were analyzed using the signiﬁcance analysis
of microarray method implemented in the TM4 suite (http://www.tm4.org/
mev/) to detect the differentially regulated genes between the living donors
and the DN samples with a false discovery rate of ,1%. The value “q” is
a multiple testing corrected P value for false positives (brieﬂy, the “q” value
method ﬁrst looks at the distribution of the P values, identiﬁes at which value
the P value becomes ﬂattened, and then incorporates this information into
the calculation of the adjusted P value).
Statistical analysis. Unless otherwise noted, the data are expressed as
means 6 SEM. Statistical analysis was performed by the t test provided by
GraphPad Prism 5.0 software (GraphPad, San Diego, CA; http://www.
graphpad.com/prism/Prism.htm). Values of P # 0.05 were considered statis-
tically signiﬁcant.
RESULTS
Microarray analysis. Normalized data of the different
p r o b es e t sb ys e t t i n gP , 0.05 on the chips generated a list
of 21 upregulated and 25 downregulated genes associated
with apoptosis in RPTs of db/db mice compared with het-
erozygous db/m+o rdb/db CAT-Tg mice (Supplementary
Tables I and II). Our raw and normalized data are available
in the public domain Gene Expression Omnibus National
Center for Biotechnology Information database (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19640).
The Gene Ontology database was used to screen for
probe sets involved in apoptotic processes. Classiﬁca-
tion was further ﬁltered by setting P , 0.01, compiling
a list of ﬁve upregulated (Table 1) and six downregulated
proapoptotic genes (Table 2) in db/db mice, compared
with db/m+a n ddb/db CAT-Tg mice. We chose Bmf in the
current study because its expression is at least threefold
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db/db CAT-Tg mice.
Validation of Bmf mRNA expression in mouse RPTs
by real-time PCR. To validate the results obtained by DNA
microarray, real-time qPCR was performed using primers
speciﬁc for mouse Bmf mRNA. Figure 1A displays the re-
sults of Bmf mRNA expression in freshly isolated RPTs
from db/m+, db/db,a n ddb/db CAT-Tg mice. The baseline
expression of Bmf mRNA in db/db mice was sixfold higher
than in db/m+m i c e( P , 0.005). This increase was signiﬁ-
cantly attenuated in db/db CAT-Tg mice (P , 0.05).
Validation of Bmf expression by immunohistochem-
istry. We previously reported TUNEL staining on kidney
sections of db/m+, db/m+ CAT-Tg, db/db,a n ddb/db CAT-Tg
mice and showed that apoptotic cells were found in RPTCs
of db/db mice but not in db/m+, db/m+C A T ,a n ddb/db CAT-
Tgs (22). To validate whether Bmf expression was increased
in RPTCs of 20-week-old T2DM db/db mice, immunohisto-
chemical analysis was performed using an anti-Bmf anti-
body. Increased immunostaining for Bmf was observed in
the RPTCs of diabetic db/db mice (Fig. 1B, b) compared with
the RPTCs of nondiabetic db/m
+ control mice (Fig. 1B, a).
CAT overexpression effectively attenuated Bmf expression,
as observed in RPTs of db/db CAT-Tg mice (Fig. 1B, c). No
immunostaining was observed with nonimmune control
serum in db/db mice (Fig. 1B, d). Quantiﬁcation of Bmf
immunostaining conﬁrmed enhanced Bmf expression in
RPTCs of db/db mice (Fig. 1C). Similarly, kidneys from adult
mice with STZ-induced diabetes also exhibited enhanced
Bmf immunostaining in RPTCs (Fig. 2A, b and B)c o m p a r e d
with nondiabetic littermates (Fig. 2A, a and B). Treatment
of diabetic mice with insulin reduced Bmf expression to
control levels (Fig. 2A, c and B). No immunostaining was
observed in sections treated with nonimmune control se-
rum (Fig. 2A, d). These results were further validated by
performing real-time qPCR for Bmf using RNA isolated from
RPTCs of STZ-induced diabetic mice. Figure 2C shows
as i g n i ﬁcant increase (P , 0.05) in Bmf mRNA expression
levels in STZ-induced diabetic mice compared with control
and insulin-treated STZ-injected mice.
HG induces ROS generation and Bmf mRNA expression
in RPTCs in vitro. Immortalized rat RPTCs were cultured
in normal glucose or HG medium with or without rotenone,
CAT, DPI, or apocynin. Cells were then harvested to assess
ROS generation with the lucigenin assay, and RNA was
isolated for real-time qPCR analysis. RPTCs cultured in
HG produced signiﬁcantly higher amounts of ROS than
RPTCs cultured in normal glucose (Fig. 3A), and these
increases could be markedly attenuated or inhibited by
r o t e n o n e ,C A T ,D P I ,o ra p o c y nin. Furthermore, RPTCs
cultured in HG medium exhibited fourfold higher Bmf
mRNA expression than RPTCs cultured in normal glucose
medium (P # 0.01; Fig. 3B). The HG-stimulated increases
in Bmf mRNA expression were inhibited by rotenone,
CAT, DPI, and apocynin.
TGF-b1 upregulates Bmf mRNA expression in rat
RPTCs. To investigate the mechanism(s) of HG-stimulation
of Bmf expression, RPTCs were cultured with active human
TGF-b1 in normal glucose medium. TGF-b1i n c r e a s e dB m f
mRNA expression in a concentration-dependent manner
(Fig. 3C). Conversely, knockdown of TGF-b1 with siRNA
attenuated HG-stimulation of Bmf mRNA expression in
RPTCs (Fig. 3D).
Cloning and amino acid sequence of rat Bmf. We
cloned Bmf cDNA from rat RPTCs (Wistar strain) by con-
ventional RT-PCR. Rat and mouse Bmf consists of 185
amino acids and is 98.9% homologous. Rat Bmf cDNA was
then subcloned into the pCMV-Myc mammalian expression
vector, which fused an NH2-terminal c-Myc epitope tag
(Supplementary Fig. 1A and B).
Bmf overexpression leads to activation of caspase-3
and RPTC apoptosis. To study the role of Bmf in apo-
ptosis, rat RPTCs were transiently transfected with
NH2-terminally Myc-tagged Bmf or an empty vector, and
TABLE 1
Proapoptotic genes upregulated in microarray chips of db/db vs. db/m+ and db/db vs. db/db CAT-Tg mice overexpressing CAT*
db/db vs. db/m+ db/db vs. db/db CAT-Tg
Probe set ID Gene title Fold-change P Fold-change P
1450231_a_at Baculoviral IAP repeat-containing 4 1.28 0.0039 1.29 0.0038
1454880_s_at Bcl2-modifying factor 3.07 0.0099 3.07 0.0098
1449297_at Caspase 12 1.82 0.0069 1.81 0.0070
1431875_a_at E2F transcription factor 1 1.19 0.0065 1.19 0.0064
1423602_at
1445452_at TNF receptor-associated factor 1 1.99 0.0073 1.97 0.0074
*The GO annotation package was used to select genes involved in the apoptosis process. The probe sets were selected with P , 0.01.
TABLE 2
Proapoptotic genes downreguated in microarray chips of db/db vs. db/m+ and db/db vs. db/db CAT-Tg mice overexpressing CAT*
db/db vs. db/m+ db/db vs. db/db CAT-Tg
Probe set ID Gene title Fold-change P Fold-change P
1417962_s_at Growth hormone receptor 22.92 0.0031 23.44 0.0024
1419592_at Unc-5 homolog C (C. elegans) 21.53 0.0058 21.39 0.0090
1435369_at U box domain-containing 5 22.10 0.0012 21.84 0.0016
1451845_a_at Peptidyl-tRNA hydrolase 2 21.88 0.0018 21.32 0.0087
1452172_at FAST kinase domains 2 22.10 0.0013 21.60 0.0027
1460671_at Glutathione peroxidase 1 21.41 0.0091 21.51 0.0063
*The GO annotation package was used to select genes involved in the apoptosis process. The probe sets were selected with P , 0.01.
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sion of the fusion protein was conﬁrmed by RT-PCR (Fig.
4A) and anti-Myc immunoblotting (Fig. 4B). Caspase-3 ac-
tivity was signiﬁcantly increased in lysates from cells tran-
siently transfected with the Bmf fusion protein compared
with lysates from cells transiently transfected with empty
vector (P , 0.005). Caspase-3 activity was further augmented
FIG. 1. Bmf expression is elevated in RPTs of db/db diabetic mice. A:
Real-time qPCR for Bmf mRNA levels in freshly isolated RPTs from
db/m, db/db,a n ddb/db CAT-Tg mice. Values were corrected to b-actin.
B: Bmf immunohistochemical (IHC) staining in kidney sections (original
magniﬁcation 3600) from (a) db/m
+,( b) db/db,a n d( c) db/db CAT-Tg
mice; (d) presents a nonimmune rabbit serum control. G, Glomerulus.
C:Q u a n t i ﬁcation of Bmf IHC staining. Values are the mean 6 SEM, n =
5–7 for each group. *P < 0.05; ***P < 0.005. N.S., not signiﬁcant. (A high-
quality color representation of this ﬁgure is available in the online issue.) FIG. 2. Bmf expression is upregulated in RPTs from STZ-induced di-
abetic mouse kidneys. A: Bmf immunohistochemical (IHC) staining in
kidney sections (original magniﬁcation 3600) from nondiabetic control
(a), STZ-induced diabetic (b), and insulin-treated STZ-injected mice
(c); nonimmune rabbit serum control is also presented (d). B: Quan-
tiﬁcation of Bmf-IHC. Values are the mean 6 SEM, n =4 –12. C: Real-
time qPCR for Bmf mRNA levels in freshly isolated RPTs from control
and STZ-induced diabetic and insulin-treated STZ-injected mice. Values
were corrected to b-actin. *P < 0.05; **P < 0.01. N.S., not signiﬁcant.
(A high-quality color representation of this ﬁgure is available in the
online issue.)
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4C). Knockdown of Bmf with siRNA reduced HG-induced
apotposis (TUNEL assay) in RPTCs compared with scram-
bled siRNA (Fig. 4D).
RPTCs transiently transfected with NH2-terminally Myc-
tagged Bmf exhibited fourfold increase in TUNEL-positive
cells compared with empty vector-transfected cells (P ,
0.005; Fig. 5A, and B). Parallel assays with lysates from
transfected cells conﬁrmed the expression of Myc-tagged
Bmf (Fig. 5C).
Bmf interacts with Bcl-2 in rat IRPTCs. To investigate
Bmf interaction with Bcl-2, coimmunoprecipitation experi-
ments of Myc-Bmf with Bcl-2 were performed. Signiﬁcant
increases in coimmunoprecipitated Bcl-2 (Fig. 5D, a)b u t
not Myc-Bmf (Fig. 5D, b) were observed in rat IRPTCs
overexpressing Myc-Bmf cultured in HG medium.
Bmf expression in diabetic human kidneys. The clini-
cal characteristics of the patients are shown in Supple-
mentary Table VI. All had kidney cancer, which was
the reason for the nephrectomies; some had T2DM, but
others did not. Immunohistochemistry revealed Bmf ex-
pression in the renal distal tubules but not in the renal
proximal tubules (RPTs) of the normal portions of human
nephrectomy specimens from nondiabetic patients with
kidney cancer (Fig. 6A, a–c). However, increased immu-
nostaining for Bmf was observed in RPTs of the normal
portions of nephrectomy specimens from patients with
kidney cancer who also had diabetes (Fig. 6A, d–f). In-
terestingly, double immunostaining revealed frequent
colocalization of Bmf overexpression in TUNEL-positive
apoptotic RPTCs in diabetic kidney but not in nondiabetic
kidney (Fig. 6B).
DNA gene chip microarray analysis (Affymetrix Gene
Chip HGU 133plus 2 chip) of microdissected nephrons
from seven patients with T2DM revealed modestly but
signiﬁcantly enhanced Bmf expression in glomeruli (1.48-
fold increase) and tubulointerstitium (1.39-fold increase)
compared with 18 control biopsy specimens from kid-
neys from living donors taken at the time of transplant
(q , 0.01, where q value is a multiple-testing corrected
FIG. 3. HG stimulates ROS generation and Bmf mRNA expression in rat RPTCs in vitro. A: ROS generation of RPTCs cultured in normal glucose
(5 mmol/L D-glucose plus 20 mmol/L D-mannitol) and HG (25 mmol/L D-glucose) media with various inhibitors, as indicated. Values are corrected to
lysate protein levels. B: Real-time qPCR for Bmf mRNA levels in RPTCs in vitro after treatment with normal glucose or HG and various inhibitors, as
indicated. C: Real-time qPCR for Bmf mRNA levels in RPTCs in response to active human TGF-b1. D: Real-time qPCR for Bmf mRNA levels in RPTCs
in vitro after transfection with siRNA of TGF-b1 or scrambled siRNA in normal glucose (□)a n dH G( ■) media. Values are corrected to b-actin levels.
*P < 0.05; **P < 0.01; ***P < 0.005; N.S., not signiﬁcant.
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478 DIABETES, VOL. 61, FEBRUARY 2012 diabetes.diabetesjournals.orgFIG. 4. Overexpression of rat Bmf induces caspase-3 activity in rat RPTCs in vitro. A: RPTCs were transiently transfected by lipofectamine 2000
with the empty vector, pCMV-Myc or plasmid containing NH2-terminally tagged rat Bmf cDNA (pCMV-Myc rat Bmf). Expression of the Myc-rat Bmf
mRNA was conﬁrmed by conventional RT-PCR and quantiﬁed by densitometry. B: Anti-Myc immunoblotting was also performed. The nonspeciﬁc
band serves as loading control. C: Caspase 3 activity in RPTCs transfected with empty vector (pCMV-Myc) or pCMV-Myc rat Bmf in normal glucose
(□) and HG (■) media. Values are corrected to lysate protein levels. Values are the mean 6 SEM, n =4 –8. ***P < 0.005. UV, ultraviolet. D: TUNEL
images (a–d) and quantiﬁcation of apoptotic cells (E) in vitro. After transfection with scrambled siRNA (a and c) or Bmf siRNA (b and d)i n
RPTCs cultured in normal glucose (NG, a and b)o rH G( c and d) medium, cells were ﬁxed and subjected to TUNEL (green) and DAPI (blue)
staining (original magniﬁcation 3200). White arrows indicate TUNEL-positive cells; (e) quantiﬁcation of TUNEL-positive cells (n = 3 experi-
ments). **P < 0.01; N.S., not signiﬁcant. (A high-quality color representation of this ﬁgure is available in the online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 61, FEBRUARY 2012 479FIG. 5. Overexpression of rat Bmf increases TUNEL-positive cells and coimmunoprecipitates (Co-IP) with Bcl-2 in rat RPTCs in vitro. A:R P T C sw e r e
transiently transfected with the empty vector, pCMV-Myc, or pCMV-Myc rat Bmf. Cells were incubated for 24 h in 25 mmol/L D-glucose, then ﬁxed and
subjected to TUNEL and DAPI staining. TUNEL (green) and DAPI (blue) staining (original magniﬁcation 3200) are shown for RPTCs transfected
with empty vector and pCMV-Myc rat Bmf. DNase-treated cells serve as TUNEL-positive controls. Cells left untreated with terminal transferase serve
as a TUNEL-negative control. B:Q u a n t i ﬁcation of TUNEL-positive cells per ﬁeld is shown. Values are presented as percentages of TUNEL-positive
cells/total cells per ﬁeld 6 SEM (n = 8 or 9). ***P < 0.005. C: Expression of the Myc-rat Bmf fusion protein was conﬁrmed by anti-Myc immuno-
blotting, with b-actin as the loading control. D: Interaction of Myc-Bmf with Bcl-2 in rat RPTCs: (a) Immunoblotting for Bcl-2 in cytosolic fractions of
rat RPTCs before (total lysate, TL) and after Co-IP with anti-Myc; (b) immunoblotting for Myc in cytosolic fractions of rat RPTCs on the same
membrane after immunobotting for anti-Bcl-2 in panel a. The relative density of Bcl-2 or Myc in RPTCs cultured normal glucose (5 mmol/L D-glucose
plus 20 mmol/L D-mannitol DMEM) was expressed as controls (100 arbitrary units). Rabbit puriﬁed IgG (3 mg) was used as the control for Co-IP
experiments. Values are the mean 6 SEM for 4 independent experiments. ***P < 0.005; N.S., not signiﬁcant. □,n o r m a lg l u c o s e ;■,h i g hg l u c o s e
medium. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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480 DIABETES, VOL. 61, FEBRUARY 2012 diabetes.diabetesjournals.orgFIG. 6. Enhanced Bmf expression in RPTs from human kidneys from patients with diabetes. A: Bmf immunohistochemical staining in human kidney
sections (original magniﬁcation 3200) from three nondiabetic cancer patients (a, patient with papillary variant carcinoma; b, patient with clear
cell carcinoma; and c, patient with thyroid-like renal carcinoma) and three diabetic cancer patients (d, patient with papillary variant carcinoma
and evidence of DN [nodular with tubular atrophy and interstitial ﬁbrosis]; e, patient with clear cell carcinoma and no evidence of DN; and f,
patient with clear cell carcinoma and nephroangiosclerosis with evidence of DN [secondary focal glomerulosclerosis, tubular atrophy, and in-
terstitial ﬁbrosis]). DT, distal tubule; G, glomerulus. B: Colocalization of Bmf expression and TUNEL-positive cells in human kidneys. Nondiabetic
human kidney (patient I.D. #C,) and diabetic human kidney with DN (patient I.D. #D) were sectioned, subjected to TUNEL assay to visualize
apoptotic cells (green), and then incubated with anti-Bmf antibody, followed by anti-goat AlexaFluor 594 to demonstrate Bmf expression (red).
Cells staining positively for TUNEL and Bmf appear yellow (merged image). Original magniﬁcation 3200. Arrows indicate cells that stained
positively for TUNEL and Bmf. G, glomerulus; DT, distal tubule. (A high-quality color representation of this ﬁgure is available in the online issue.)
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characteristics of the patients in the gene microarray
analysis.
DISCUSSION
The current study documents enhanced Bmf expression
in RPTCs of db/db mice, STZ-induced diabetic mice, and
kidneys from patients with T2DM and shows that Bmf
overexpression enhances RPTC apoptosis, indicating a
potential role for Bmf in mediating tubular atrophy in the
diabetic kidney.
To identify the proapoptotic genes regulated by ROS in
db/db mice RPTCs, we used gene chip microarrays as an
initial screen (37). A combination of high P values, fold
changes, and Gene Ontology annotation (32) allowed us to
obtain an overview of the genetic regulation of RPTC ap-
optosis occurring in murine models of T2DM.
We identiﬁed Bmf as one of ﬁve putative proapoptotic
genes that were differentially upregulated (P , 0.01 and
.1.5-fold increase) in RPTs of db/db mice compared with
db/m+ and db/db CAT-Tg mice. The upregulation of Bmf
mRNA and protein expression in RPTCs of db/db mice was
conﬁrmed by real-time qPCR and immunostaining.
To conﬁrm enhanced Bmf expression, we used an-
other model of diabetes, STZ-induced diabetes in mice
(20). Our results document signiﬁcant upregulation of Bmf
expression in RPTCs of STZ-induced diabetes and its re-
versal by insulin.
There is evidence that HG induces apoptosis in RPTCs
via ROS generation (20,38). Our present data show that
HG also stimulates Bmf mRNA expression, which can be
inhibited by rotenone, CAT, DPI, and apocynin. Cellular
H2O2 and mitochondrial ROS levels were also signiﬁcantly
higher in RPTCs incubated in HG medium than in RPTCs
cultured in normal glucose and were normalized in the
presence of CAT (Supplementary Fig 2a and b). These ob-
servations indicate that ROS derived from mitochondrial ox-
idative metabolism may mediate, at least in part, HG-induced
Bmf expression, which in turn would promote RPTC
apoptosis.
To provide evidence that Bmf can directly induce RPTC
apoptosis, we overexpressed Bmf in rat RPTCs. Transient
transfection of RPTCs with rat Bmf cDNA resulted in ac-
tivation of caspase-3 parallel with increases in the number
of apoptotic cells, similar to that observed in transfected
ﬁbroblasts and cancer cells (39). We were unable to detect
increases in endogenous rat Bmf expression in RPTCs by
immunoblotting or immunoﬂuorescence (data not shown)
using the same anti-Bmf antibodies used for immunohisto-
chemistry. Of note, Schmelzle et al. (40) also observed that
commercially available anti-Bmf antibodies do not work in
immunoblotting versus immunohistochemistry of Bmf.
The precise mechanism(s) by which HG evokes Bmf ex-
pression in RPTC apoptosis remains unclear. Our present
data show that TGF-b1 stimulates Bmf mRNA expression
and that knockdown of TGF-b1 with siRNA attenuates Bmf
mRNA expression in RPTCs in HG. These observations are
consistent with ﬁndings of Ramjaun et al. (41) showing that
TGF-b1 stimulates Bmf gene expression. ROS could induce
phosphorylation of Bmf via c-Jun NH2-terminal kinase (42)
or other signaling pathways. Phosphorylated Bmf would
then translocate from the cytoskeleton to bind antiapoptotic
proteins (i.e., Bcl-2 and Bcl-xL), which are located on the
mitochondria, to interfere with Bcl-2/Bcl-xL mitochondrial
gatekeeping and thus allow enhanced Bax binding to the
mitochondrion. This would result in the collapse of the
mitochondrial transmembrane potential and thus activa-
tion of the intrinsic pathway of apoptosis. Our ﬁndings
that Myc-Bmf coimmunoprecipitates Bcl-2 in rat RPTCs
lend further support to this notion.
We searched the publicly accessible National Center for
Biotechnology Information data bank (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE1009) for microarray
studies performed on biopsy specimens from patients with
DN (Supplementary Table V) to conﬁrm our ﬁndings in db/db
mice. Bmf was not detectable, however, in human kidneys
from patients with diabetes when the ﬁrst generation of
chips (Affymetrix Human Genome U95 Version 2 Array)
was used because a Bmf probeset was not present in these
chips. Bmf expression was upregulated, however, in kidney
allografts from living donors compared with at implantation
before revascularization (0 months) using the Affymetrix
Human Genome U133 Plus 2.0 Array (Affy 133plus chip),
which contains the Bmf probeset. These ﬁndings indicate
that Bmf expression may be upregulated in human kid-
neys under pathologic conditions, including DN.
Indeed, this possibility is supported by our immunohis-
tochemistry studies that show increased Bmf expression
in RPTs taken from nonmalignant portions of kidneys re-
moved removed from diabetic patients due to kidney can-
cer compared with those taken from nondiabetic patients
with kidney cancer. Interestingly, RPTCs overexpressing
Bmf frequently stained positive for TUNEL in diabetic hu-
man kidney. Furthermore, the Affy 133plus chip assay re-
vealed signiﬁcantly upregulated Bmf expression (q , 0.01,
where q value is a multiple testing corrected P value) in
microdissected glomeruli (1.48-fold increase) and tubulo-
interstitium (1.39-fold increase) from patients with T2DM
compared with nondiabetic patients (kidney donors). The
1.39-fold versus 3-fold increases in Bmf expression in
human diabetic tubulointerstitium and db/db mice RPTs,
respectively, are difﬁcult to reconcile. It is possible that
Bmf mRNA expression in human tubulointestitium might
have been underestimated because of the use of a mix-
ture of tubules and interstitium versus the .90% purity of
our db/db mouse RPT fraction. Additional qPCR studies
are needed to compare Bmf expression in human RPTs
with or without T2DM.
Our results may have clinical implications for patients
with T2DM. Because tubular apoptosis is one of the char-
acteristic morphologic changes in human diabetic kidneys
(15–17) and tubular atrophy appears to be a better indicator
of disease progression than glomerular pathology (2–4), we
suggest that RPTC apoptosis may be an initial mechanism
for tubular atrophy in T2DM. Our present data point toward
Bmf as one of the mediators of this process. However,
whether enhanced Bmf expression directly or indirectly
induces RPTC apoptosis in human T2DM remains to be
investigated.
In summary, the current study suggests an important
role for Bmf in mediating RPTC apoptosis in the diabetic
mouse kidney in vivo, and, likely, in diabetic human kid-
neys. Our observations raise the possibility that selective
targeting of this proapoptotic protein may provide a novel
approach in preventing or reversing the pathologic mani-
festations of DN, particularly tubular atrophy.
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